The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Subscribe To Our Newsletter & Stay Updated
